GLP-1 receptor in Obesity
- Primary identifiers
- 6
- Sponsors tracked
- 6
- Evidence types
- 2 of 3
- Last refreshed
- 2026-07-28 · monthly
MightyRayn panel synthesis
OmniRayn’s reading of this landscape — our interpretation, not a registry fact
The efficacy contest at the top of this field is effectively settled, which means a new molecule must now differentiate on something other than weight lost. Two axes are visibly contested in the registry: route and dosing interval — oral non-peptide entrants and a weekly-to-monthly programme both appear here — and the comorbid population served. What the record does not yet establish is durable differentiation on the QUALITY of weight lost, which is tracked on our lean-mass landscape. Read the two pages together: they compete for the same prescription.
Programs and primary evidence
| Sponsor | Asset | Phase | Mechanism | Primary source |
|---|---|---|---|---|
| Pfizer | MET097 | 2 | long-acting GLP-1 receptor agonist |
|
| Structure Therapeutics (Gasherbrum Bio) | Aleniglipron | 3 | oral non-peptide GLP-1 receptor agonist |
|
| Kailera | KAI-9531 (ribupatide) | 3 | weekly injectable incretin agonist |
|
| Verdiva Bio | Ecnoglutide (VRB-101) | 2 | weekly oral GLP-1 receptor agonist |
|
| Hangzhou Sciwind Biosciences | XW003 (ecnoglutide) | 3 | injectable GLP-1 receptor agonist |
|
| Mount Sinai Hospital / University of Toronto | review | — | mechanistic and pharmacological review |
|
Method and limits
- Programs are enumerated from primary registries (ClinicalTrials.gov, PubMed). A program appears here only if a primary record links this target to this indication as a therapeutic hypothesis — associations and risk markers are excluded by design.
- Every claim above carries the identifier it rests on. We report what the record states; we do not assert efficacy, and computational findings are pending wet-lab confirmation.
- Absence is not evidence of absence: unregistered, non-US and stealth-stage programs are not visible to these sources.
- This page refreshes monthly (no net-new primary entity in 27 days). Mechanism classifications are our reading of the public record and may be revised.
Want the analysis behind this landscape?
The public page is the map. The full dossier adds differentiation analysis, kill-tests and the whitespace read for this target — the parts we do not publish.